Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 1
1954 1
1955 2
1957 2
1958 2
1961 1
1962 2
1963 10
1964 12
1965 14
1966 23
1967 22
1968 24
1969 21
1970 8
1971 19
1972 19
1973 9
1974 16
1975 11
1976 12
1977 15
1978 34
1979 20
1980 33
1981 36
1982 42
1983 47
1984 49
1985 52
1986 58
1987 57
1988 72
1989 85
1990 89
1991 101
1992 97
1993 106
1994 84
1995 86
1996 85
1997 116
1998 111
1999 116
2000 142
2001 144
2002 124
2003 126
2004 141
2005 164
2006 147
2007 185
2008 181
2009 182
2010 175
2011 211
2012 225
2013 265
2014 239
2015 230
2016 234
2017 263
2018 270
2019 312
2020 339
2021 360
2022 222
Text availability
Article attribute
Article type
Publication date

Search Results

6,102 results
Results by year
Filters applied: . Clear all
Page 1
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, Kumagai S, Shibata Y, Hayashida T, Watanabe K, Fukuhara T, Ikeda T, Yoh K, Kato T, Nishino K, Nakamura A, Nakachi I, Kuyama S, Furuya N, Sakakibara-Konishi J, Okamoto I, Taima K, Ebi N, Daga H, Yamasaki A, Kodani M, Udagawa H, Kirita K, Zenke Y, Nosaki K, Sugiyama E, Sakai T, Nakai T, Ishii G, Niho S, Ohtsu A, Kobayashi SS, Goto K. Izumi H, et al. Among authors: ikeda t. Nature. 2021 Dec;600(7888):319-323. doi: 10.1038/s41586-021-04135-5. Epub 2021 Nov 24. Nature. 2021. PMID: 34819663 Free PMC article.
SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity.
Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, Ngare I, Kimura I, Uriu K, Kosugi Y, Yue Y, Shimizu R, Ito J, Torii S, Yonekawa A, Shimono N, Nagasaki Y, Minami R, Toya T, Sekiya N, Fukuhara T, Matsuura Y, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium, Ikeda T, Nakagawa S, Ueno T, Sato K. Motozono C, et al. Among authors: ikeda t. Cell Host Microbe. 2021 Jul 14;29(7):1124-1136.e11. doi: 10.1016/j.chom.2021.06.006. Epub 2021 Jun 15. Cell Host Microbe. 2021. PMID: 34171266 Free PMC article.
Sulfide catabolism ameliorates hypoxic brain injury.
Marutani E, Morita M, Hirai S, Kai S, Grange RMH, Miyazaki Y, Nagashima F, Traeger L, Magliocca A, Ida T, Matsunaga T, Flicker DR, Corman B, Mori N, Yamazaki Y, Batten A, Li R, Tanaka T, Ikeda T, Nakagawa A, Atochin DN, Ihara H, Olenchock BA, Shen X, Nishida M, Hanaoka K, Kevil CG, Xian M, Bloch DB, Akaike T, Hindle AG, Motohashi H, Ichinose F. Marutani E, et al. Among authors: ikeda t. Nat Commun. 2021 May 25;12(1):3108. doi: 10.1038/s41467-021-23363-x. Nat Commun. 2021. PMID: 34035265 Free PMC article.
Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study.
GBD 2017 US Neurological Disorders Collaborators, Feigin VL, Vos T, Alahdab F, Amit AML, Bärnighausen TW, Beghi E, Beheshti M, Chavan PP, Criqui MH, Desai R, Dhamminda Dharmaratne S, Dorsey ER, Wilder Eagan A, Elgendy IY, Filip I, Giampaoli S, Giussani G, Hafezi-Nejad N, Hole MK, Ikeda T, Owens Johnson C, Kalani R, Khatab K, Khubchandani J, Kim D, Koroshetz WJ, Krishnamoorthy V, Krishnamurthi RV, Liu X, Lo WD, Logroscino G, Mensah GA, Miller TR, Mohammed S, Mokdad AH, Moradi-Lakeh M, Morrison SD, Shivamurthy VKN, Naghavi M, Nichols E, Norrving B, Odell CM, Pupillo E, Radfar A, Roth GA, Shafieesabet A, Sheikh A, Sheikhbahaei S, Shin JI, Singh JA, Steiner TJ, Stovner LJ, Wallin MT, Weiss J, Wu C, Zunt JR, Adelson JD, Murray CJL. GBD 2017 US Neurological Disorders Collaborators, et al. Among authors: ikeda t. JAMA Neurol. 2021 Feb 1;78(2):165-176. doi: 10.1001/jamaneurol.2020.4152. JAMA Neurol. 2021. PMID: 33136137 Free PMC article.
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, Yamasoba D, Gerber PP, Fatihi S, Rathore S, Zepeda SK, Papa G, Kemp SA, Ikeda T, Toyoda M, Tan TS, Kuramochi J, Mitsunaga S, Ueno T, Shirakawa K, Takaori-Kondo A, Brevini T, Mallery DL, Charles OJ; CITIID-NIHR BioResource COVID-19 Collaboration; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ecuador-COVID19 Consortium, Bowen JE, Joshi A, Walls AC, Jackson L, Martin D, Smith KGC, Bradley J, Briggs JAG, Choi J, Madissoon E, Meyer KB, Mlcochova P, Ceron-Gutierrez L, Doffinger R, Teichmann SA, Fisher AJ, Pizzuto MS, de Marco A, Corti D, Hosmillo M, Lee JH, James LC, Thukral L, Veesler D, Sigal A, Sampaziotis F, Goodfellow IG, Matheson NJ, Sato K, Gupta RK. Meng B, et al. Among authors: ikeda t. Nature. 2022 Mar;603(7902):706-714. doi: 10.1038/s41586-022-04474-x. Epub 2022 Feb 1. Nature. 2022. PMID: 35104837 Free PMC article.
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, Morioka Y, Nao N, Nasser H, Uriu K, Kosugi Y, Tsuda M, Orba Y, Sasaki M, Shimizu R, Kawabata R, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K; Genotype to Phenotype Japan (G2P-Japan) Consortium, Sawa H, Ikeda T, Irie T, Matsuno K, Tanaka S, Fukuhara T, Sato K. Suzuki R, et al. Among authors: ikeda t. Nature. 2022 Mar;603(7902):700-705. doi: 10.1038/s41586-022-04462-1. Epub 2022 Feb 1. Nature. 2022. PMID: 35104835 Free PMC article.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: ikeda t. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.
Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Loeber S, Tsuda M, Wang L, Ozono S, Butlertanaka EP, Tanaka YL, Shimizu R, Shimizu K, Yoshimatsu K, Kawabata R, Sakaguchi T, Tokunaga K, Yoshida I, Asakura H, Nagashima M, Kazuma Y, Nomura R, Horisawa Y, Yoshimura K, Takaori-Kondo A, Imai M; Genotype to Phenotype Japan (G2P-Japan) Consortium, Tanaka S, Nakagawa S, Ikeda T, Fukuhara T, Kawaoka Y, Sato K. Saito A, et al. Among authors: ikeda t. Nature. 2022 Feb;602(7896):300-306. doi: 10.1038/s41586-021-04266-9. Epub 2021 Nov 25. Nature. 2022. PMID: 34823256 Free PMC article.
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, Uriu K, Tsuda M, Zahradnik J, Shirakawa K, Suzuki R, Kishimoto M, Kosugi Y, Kobiyama K, Hara T, Toyoda M, Tanaka YL, Butlertanaka EP, Shimizu R, Ito H, Wang L, Oda Y, Orba Y, Sasaki M, Nagata K, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Kuramochi J, Seki M, Fujiki R, Kaneda A, Shimada T, Nakada TA, Sakao S, Suzuki T, Ueno T, Takaori-Kondo A, Ishii KJ, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium, Sawa H, Saito A, Irie T, Tanaka S, Matsuno K, Fukuhara T, Ikeda T, Sato K. Yamasoba D, et al. Among authors: ikeda t. Cell. 2022 Jun 9;185(12):2103-2115.e19. doi: 10.1016/j.cell.2022.04.035. Epub 2022 May 2. Cell. 2022. PMID: 35568035 Free PMC article.
Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
Kaku Y, Kuwata T, Zahid HM, Hashiguchi T, Noda T, Kuramoto N, Biswas S, Matsumoto K, Shimizu M, Kawanami Y, Shimura K, Onishi C, Muramoto Y, Suzuki T, Sasaki J, Nagasaki Y, Minami R, Motozono C, Toyoda M, Takahashi H, Kishi H, Fujii K, Tatsuke T, Ikeda T, Maeda Y, Ueno T, Koyanagi Y, Iwagoe H, Matsushita S. Kaku Y, et al. Among authors: ikeda t. Cell Rep. 2021 Jul 13;36(2):109385. doi: 10.1016/j.celrep.2021.109385. Epub 2021 Jun 25. Cell Rep. 2021. PMID: 34237284 Free PMC article.
6,102 results